The progress of EDIT-301 in Phase 1/2 RUBY and EdiTHAL studies is encouraging. I am increasingly turning more bearish on EDIT due to increased competition and a less attractive financial outlook. The ...

Sizable investments. High-profile appearances at industry events. Unique development platforms. These elements would augur well for companies of any kind—and companies hoping to bring epigenome ...

Editas Medicine (NASDAQ:EDIT) is one of the best gene-editing stocks to buy according to hedge funds. On November 10, 2025, Clear Street raised its price target on Editas Medicine (NASDAQ:EDIT) to ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Editas Medicine reported promising initial results from the EDIT-301 trials for inherited blood disorders, leading to a rating upgrade to "outperform" by Raymond James. The company's financial ...

SEATTLE — May 13, 2024 — Researchers at Fred Hutch Cancer Center have found in pre-clinical studies that an experimental gene therapy for genital and oral herpes removed 90% or more of the infection ...

CAMBRIDGE, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly ...

Details progress on ocular programs, including EDIT-101 Phase 1/2 BRILLIANCE trial updates Provides EDIT-301 updates, including timeline for dosing sickle cell disease patients in the Phase 1/2 RUBY ...

Intellia Therapeutics NTLA reported second-quarter results in line with our expectations, and its pipeline candidates are continuing to progress in development. Collaboration revenue totaled $13.6 ...

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported pipeline ...